Interferon ¥â-1a ÁÖ»çÁ¦(Ç°¸í: ·¹ºñÇÁÇÁ¸®ÇʵåÁÖ»ç, ·¹ºñµµÁîÇÁ¸®ÇʵåÆæ, ¾Æº¸³Ø½ºÁÖ µî) ¡á °í½Ã °³Á¤ Àüü³»¿ë °¢ ¾àÁ¦º° Çã°¡»çÇ× ¹üÀ§ ³»¿¡¼ ¾Æ·¡¿Í °°Àº ±âÁØÀ¸·Î Åõ¿© ½Ã ¿ä¾ç±Þ¿©¸¦ ÀÎÁ¤Çϸç, µ¿ ÀÎÁ¤±âÁØ ÀÌ¿Ü¿¡´Â ¾à°ª Àü¾×À» ȯÀÚ°¡ ºÎ´ãÅä·Ï ÇÔ. - ¾Æ ·¡ -
°¡. Åõ¿© ´ë»ó 1) McDonald(`17) Áø´Ü±âÁØ(½Ã°£ÆÄÁ¾(Dissemination in time, DIT)°ú °ø°£ÆÄÁ¾(Dissemination in space, DIS)À» ÃæÁ·)¿¡ ºÎÇÕÇÏ¸é¼ ´Ù¸¥ À¯»çÁúȯ¿¡ ÀÇÇÑ ¹ß»ýÀ» ¹èÁ¦ÇÒ ¼ö ÀÖ´Â Àç¹ß¿ÏÈÇü ´Ù¹ß°æÈÁõ ȯÀÚ 2) ÀÌÂ÷ ÁøÇ༺ ´Ù¹ß°æÈÁõ ȯÀÚ 3) ´Ù¸¥ ÁúȯÀ¸·Î ¼³¸íµÇÁö ¾Ê´Â Å»¼öÃʼº Brain MRI ¼Ò°ßÀÌ ÀÖ°í ³ú ¶Ç´Â ô¼ö¿¡ 2°³ ÀÌ»óÀÇ lesionÀ» °¡Áø °æ¿ì·Î¼, ´Ù¹ß°æÈÁõÀ¸·Î ÁøÇàµÉ È®·üÀÌ ³ôÀº CIS ȯÀÚ(Clinically isolated syndrome, ÀÓ»óÀûÀ¸·Î ´Ü¹ß¼º º´º¯ÀÌ ÀÖ´Â ÁõÈıº)
³ª. Åõ¿©ÁßÁö ±âÁØ 1) ½Å°æ°úÀü¹®ÀÇ°¡ ÁøÂûÇÏ¿© 12°³¿ù À̳»¿¡ 2ȸÀÇ ½ÉÇÑ ¼Õ»óÀÌ À¯¹ßµÇ´Â Àç¹ßÀÌ ÀÖ´Â °æ¿ì(Two disabling relapses, as defined by the examining neurologist, within a 12 month period) 2) 6°³¿ù¿¡ °ÉÃÄ °üÂûÇÒ ¼ö ÀÖ´Â ¼Õ»óÀÌ Áõ°¡ÇÏ´Â ÀÌÂ÷ÀûÀÎ ÁøÇà »óÅÂ(Secondary progression with an increase in disability observable over 6 months) 3) 6°³¿ù°£ Áö¼ÓÀûÀ¸·Î º¸Çà ´É·ÂÀÌ ³ªºüÁ® °ÉÀ» ¼ö ¾øÀ» ¶§(Loss of ability to walk, with or without assistance, persistent for at least 6 months) ´Ù. ÁßÁö±âÁØ¿¡ ÇØ´çÇÏÁö ¾Ê´Â °æ¿ì¿¡´Â Åõ¿©±â°£ÀÇ Á¦ÇÑ ¾øÀÌ °è¼Ó Åõ¿©¸¦ ÀÎÁ¤ÇÔ.
¡á °í½Ã °³Á¤ °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2021-26È£(2021.2.1.) ¡á °í½Ã °³Á¤ »çÀ¯ ±³°ú¼, °¡À̵å¶óÀÎ, ÀÓ»ó¹®Çå, Á¦¿Ü±¹ º¸Çè±âÁØ, ÇÐȸÀÇ°ß µî ÂüÁ¶ÇÏ¿©, °¢ ¾àÁ¦º° Çã°¡»çÇ× ¹üÀ§ ³»¿¡¼Åõ¿©´ë»óÀ» McDonald Áø´Ü±âÁØÀ» ÃæÁ·ÇÏ´Â Àç¹ß¿ÏÈÇü ȯÀÚ·Î È®´ë ¹× CIS Áø´Ü ¿ä°Ç ¹®±¸¸¦ ¸íÈ®È÷ ÇÔ. ¡á º¯°æ Àü °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2017-35È£(2017.3.1.)3-2 Ãâó : °Ç°º¸Çè½É»çÆò°¡¿ø |